A federal ban on most hemp-derived THC products will be delayed for one month after the Senate voted to table a bipartisan amendment that sought to remove the delay from stopgap government funding legislation.
The Senate voted 61-32 Thursday to table an amendment from Sen. Ted Budd (R-N.C.) and approximately a dozen other senators that would have stripped the delay provision from the continuing resolution, allowing the ban on hemp-derived THC products to take effect sooner.
Hemp-derived THC products include items such as beverages, gummies, and other consumables that use cannabinoids extracted from hemp plants. The original deadline for enforcement was set for August 14 before the one-month reprieve was added.
What the Right Is Saying
Conservative Republicans backing the Budd amendment called the delay a capitulation to special interests at the expense of public health and regulatory consistency.
Sen. Tommy Tuberville (R-Ala.) argued that the Drug Enforcement Administration had already provided adequate notice and that further delays create uncertainty for law enforcement agencies trying to enforce controlled substance laws.
Industry groups representing hemp businesses welcomed the delay but expressed frustration with ongoing regulatory ambiguity, saying Congress should use the extra time to provide clearer statutory guidance rather than temporary patches.
What the Left Is Saying
Senate Democrats who supported the delay argued that a more deliberate regulatory process is needed to protect consumers and allow the industry time to comply with new rules.
Sen. Jeff Merkley (D-Ore.), a vocal opponent of immediate implementation, said the extension provides necessary breathing room for small businesses and farmers who have invested in hemp production based on existing federal guidelines.
Consumer safety advocates aligned with progressive groups emphasized that rushing enforcement could push products into an unregulated gray market without proper quality controls or age restrictions.
What the Numbers Show
The Senate vote to table the amendment was 61-32, meaning it fell short of the simple majority needed to advance.
Hemp-derived THC products became a legal gray area after the 2018 Farm Bill legalized hemp but did not explicitly address intoxicating cannabinoids derived from the plant.
According to industry estimates, the U.S. hemp-derived CBD and cannabinoid market generates approximately $5 billion in annual revenue, with THC-containing products representing a growing share of that total.
The one-month delay pushes enforcement of DEA restrictions until October 19, setting up another potential funding fight when the continuing resolution expires.
The Bottom Line
The Senate vote preserves the status quo for hemp-derived THC products for another month, but does not resolve underlying questions about how these items should be regulated under federal drug law.
Congress will face the issue again before mid-October when the stopgap spending measure expires. Lawmakers could attach permanent guidance to a full-year funding bill or another continuing resolution.
The outcome will affect a rapidly growing industry and thousands of businesses that have built operations around products whose legal status remains contested between the 2018 Farm Bill and decades-old controlled substance statutes.